These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203 [TBL] [Abstract][Full Text] [Related]
3. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660 [TBL] [Abstract][Full Text] [Related]
4. A benefit-risk assessment of class III antiarrhythmic agents. Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415 [TBL] [Abstract][Full Text] [Related]
5. Azimilide dihydrochloride: a unique class III antiarrhythmic agent. Tran HT Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612 [TBL] [Abstract][Full Text] [Related]
7. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm. Fuchs T; Groysman R; Meilichov I Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469 [TBL] [Abstract][Full Text] [Related]
8. Amiodarone in the prevention and treatment of arrhythmia. Auer J; Berent R; Eber B Curr Opin Investig Drugs; 2002 Jul; 3(7):1037-44. PubMed ID: 12186264 [TBL] [Abstract][Full Text] [Related]
9. Clinical differences between the newer antiarrhythmic agents. Camm AJ Europace; 2000 Jul; 1 Suppl C():C16-22. PubMed ID: 11220520 [TBL] [Abstract][Full Text] [Related]
10. A benefit-risk assessment of class III antiarrhythmic agents. Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126 [TBL] [Abstract][Full Text] [Related]
11. Azimilide dihydrochloride, a novel antiarrhythmic agent. Karam R; Marcello S; Brooks RR; Corey AE; Moore A Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222 [TBL] [Abstract][Full Text] [Related]
16. The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. Lin C; Ke X; Cvetanovic I; Ranade V; Somberg J Cardiology; 2007; 108(1):18-27. PubMed ID: 16960444 [TBL] [Abstract][Full Text] [Related]
17. Recent developments in cardiovascular drug therapy: treatment of atrial arrhythmias with new class III drugs and beyond. Pürerfellner H Curr Med Chem Cardiovasc Hematol Agents; 2004 Jan; 2(1):79-91. PubMed ID: 15320809 [TBL] [Abstract][Full Text] [Related]
18. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. Kühlkamp V; Mewis C; Suchalla R; Mermi J; Dörnberger V; Seipel L Int J Cardiol; 1999 Jun; 69(3):271-9. PubMed ID: 10402110 [TBL] [Abstract][Full Text] [Related]
19. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility. Singh BN J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235 [TBL] [Abstract][Full Text] [Related]
20. The azimilide post-infarct survival evaluation (ALIVE) trial. Camm AJ; Karam R; Pratt CM Am J Cardiol; 1998 Mar; 81(6A):35D-39D. PubMed ID: 9537221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]